List of Excipients in Branded Drug TIROSINT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
IBSA Pharma Inc	TIROSINT	levothyroxine sodium	71858-0005	GELATIN
IBSA Pharma Inc	TIROSINT	levothyroxine sodium	71858-0005	GLYCERIN
IBSA Pharma Inc	TIROSINT	levothyroxine sodium	71858-0005	WATER

Tirosint Excipient Strategy and Commercial Opportunities in Levothyroxine Softgel and Oral-Solution Markets

Last updated: September 5, 2026

Tirosint is a differentiated levothyroxine product built around a minimal-excipient formulation. Tirosint capsules use levothyroxine sodium in a softgel containing gelatin, glycerin, and water. Tirosint-SOL is an oral solution supplied in single-dose ampules and uses glycerol, water, and ethanol as inactive ingredients.[1][2]

The commercial opportunity is concentrated in patients who report intolerance to tablet excipients, experience inconsistent thyroid-stimulating hormone control, have absorption problems, or require precise liquid dosing. The strongest competitive defenses are formulation know-how, device and packaging integration, manufacturing consistency, physician familiarity, and market access rather than the intrinsic complexity of levothyroxine itself.

What excipients are used in Tirosint capsules?

Tirosint capsules contain three inactive ingredients:

Component	Functional role	Commercial relevance
Gelatin	Softgel shell and dosage-form matrix	Enables a compact, sealed dosage form with few inactive ingredients
Glycerin	Plasticizer and humectant	Provides capsule flexibility and supports shell integrity
Water	Processing and shell component	Supports gelatin hydration and softgel formation
Levothyroxine sodium	Active pharmaceutical ingredient	Thyroid hormone replacement

The capsule formulation excludes several common tablet excipients, including lactose, sugars, dyes, starch, and talc. The product is marketed as gluten-free and as having no artificial colors.[1]

The excipient profile is commercially important because many levothyroxine tablets contain fillers, binders, coatings, colorants, and disintegrants. Tirosint’s short ingredient list supports positioning for patients with excipient sensitivity, dietary restrictions, dysphagia, gastrointestinal comorbidities, or difficulty maintaining stable thyroid levels.

The formulation does not eliminate all patient-specific considerations. Gelatin may matter for patients avoiding animal-derived materials, and the capsule remains unsuitable for patients who require a liquid formulation or have difficulty swallowing softgels.

What excipients are used in Tirosint-SOL?

Tirosint-SOL is a liquid levothyroxine formulation supplied in unit-dose ampules. Its inactive ingredients are glycerol, water, and ethanol.[2]

Component	Functional role	Product strategy
Glycerol	Solvent, humectant, and viscosity modifier	Supports liquid formulation and dose uniformity
Water	Vehicle	Provides the aqueous phase
Ethanol	Co-solvent and formulation aid	Supports solubilization and product stability
Levothyroxine sodium	Active pharmaceutical ingredient	Delivered as a measured oral solution

Tirosint-SOL uses a lower-excipient approach than conventional liquid medicines that may contain sugars, preservatives, flavor systems, or suspending agents. Its unit-dose presentation reduces measuring variability and supports use in pediatrics, geriatrics, enteral-feeding settings, and patients who cannot swallow tablets or capsules.

The ethanol content has commercial implications. It may require review by prescribers and caregivers in pediatric populations, affect institutional formulary decisions, and influence the design of competing formulations. A rival product that removes ethanol while maintaining solubility, stability, and dose uniformity could create a meaningful differentiation point.

How does the Tirosint formulation compare with levothyroxine tablets?

Tirosint competes against generic levothyroxine tablets, branded Synthroid, Unithroid, Levoxyl, and other oral formulations. The active ingredient is the same, but the excipient system and dosage form differ.

Attribute	Tirosint capsule	Tirosint-SOL	Conventional tablet
Dosage form	Softgel capsule	Unit-dose oral solution	Compressed tablet
Core excipients	Gelatin, glycerin, water	Glycerol, water, ethanol	Varies by manufacturer
Dyes	None in listed formulation	None in listed formulation	May be present
Lactose or sugar	None listed	None listed	May vary
Dose flexibility	Available in multiple strengths	Broad liquid dosing flexibility	Strength-based dosing
Swallowing burden	Lower than tablets but still present	Minimal	Higher
Manufacturing complexity	Softgel encapsulation	Solution preparation and ampule filling	Tablet compression and coating
Primary differentiation	Minimal excipients and softgel delivery	Liquid delivery and minimal excipients	Low cost and broad availability

Tirosint’s principal formulation advantage is dose consistency in a dosage form that may be less affected by tablet disintegration and excipient variability. Clinical performance still depends on administration timing, concomitant medicines, gastrointestinal conditions, adherence, and appropriate thyroid monitoring.[3]

The commercial claim should therefore focus on formulation suitability and patient-management benefits, not on a universal superiority claim over all levothyroxine tablets.

What commercial opportunities exist for Tirosint excipient strategy?

Patients with excipient sensitivity

Patients who report reactions to lactose, dyes, gluten-containing ingredients, or other tablet excipients are a clear target segment. Tirosint’s limited ingredient list gives prescribers a practical alternative when the specific excipient in a tablet is unknown, inconsistent across manufacturers, or difficult to identify.

This segment supports premium pricing, specialty-pharmacy distribution, and targeted physician education. The opportunity is strongest where the cost of repeated switching, symptom attribution, laboratory retesting, or nonadherence exceeds the product’s price premium.

Patients with absorption or administration problems

Tirosint and Tirosint-SOL can be positioned for patients with:

• Bariatric surgery history
• Celiac disease or other gastrointestinal disorders
• Proton-pump inhibitor use
• Polypharmacy
• Dysphagia
• Enteral feeding requirements
• Pediatric dosing needs
• Difficulty maintaining stable thyroid-stimulating hormone levels

Tirosint-SOL has particular relevance where a patient cannot reliably swallow a tablet or capsule. A measured liquid can also simplify dose adjustment in children and patients requiring doses between standard tablet strengths.

Pediatric and geriatric formulations

The liquid format creates a strong age-segment opportunity. Pediatric patients often require weight-based or finely titrated doses. Elderly patients may have dysphagia, polypharmacy, or difficulty following fasting instructions.

A future product could expand this opportunity through:

• Preservative-free multidose packaging
• Lower-volume unit doses
• Child-resistant packaging
• Oral syringes with dose markings
• Flavor-free and flavored versions
• Dosing schedules integrated with pediatric treatment protocols

The primary technical risks are dose adsorption to delivery devices, content uniformity at low concentrations, microbial control, and packaging accuracy.

Hospital and institutional use

Tirosint-SOL can address institutional needs where tablets must be crushed, dispersed, or administered through feeding tubes. A ready-to-use liquid may reduce preparation steps and dosing errors.

Institutional adoption depends on acquisition cost, pharmacy-and-therapeutics review, ethanol policy, tube-compatibility data, storage requirements, and reimbursement. Unit-dose ampules can improve inventory control but may increase packaging cost and waste.

What formulation patents protect Tirosint and Tirosint-SOL?

The commercial protection for Tirosint is based more heavily on formulation and dosage-form know-how than on a new-molecule patent. Levothyroxine is an established active ingredient, so product protection does not rely on new chemical entity exclusivity.

Public FDA and patent records identify patent activity directed to levothyroxine formulations, including liquid compositions and dosage forms associated with IBSA-related products.[4][5] Relevant protection may cover:

• Liquid pharmaceutical formulations of thyroid hormones
• Solubilization of levothyroxine
• Softgel dosage forms
• Excipient combinations
• Stability and dose uniformity
• Unit-dose packaging
• Methods of treating hypothyroidism with specific formulations

Patent scope must be evaluated claim by claim. A patent covering a glycerol-water-ethanol solution may not block a competing aqueous suspension, tablet, powder-for-reconstitution product, or softgel using a different shell system.

Orange Book and FDA exclusivity

Tirosint and Tirosint-SOL are FDA-approved prescription products. Their commercial position should be assessed through the current Orange Book patent listings, FDA labeling, and Drugs@FDA approval history.[1][2][6]

The key regulatory distinction is that levothyroxine does not receive the standard five-year new chemical entity exclusivity associated with a novel active molecule. Product-specific exclusivity can instead arise from new clinical investigations, pediatric studies, orphan status, or other statutory categories where applicable.

FDA approval alone does not establish that all relevant patents are listed in the Orange Book. Formulation, packaging, manufacturing, and process patents may have limited or no Orange Book relevance depending on whether they claim the approved drug product or an approved method of use.

When does Tirosint lose exclusivity?

Tirosint’s market protection has multiple layers:

Protection layer	Relevance to Tirosint
Active-ingredient exclusivity	Limited because levothyroxine is an established drug
FDA regulatory exclusivity	Depends on the specific NDA and qualifying studies
Formulation patents	Potentially important for softgel and oral-solution products
Method-of-use patents	May protect defined patient or dosing uses
Trade secrets	Important for manufacturing parameters and quality control
Brand recognition	Supports continued prescribing after patent expiry
Distribution access	Supports specialty positioning and patient retention

A generic applicant may enter before patent expiry through a Paragraph IV certification if it argues that listed patents are invalid, unenforceable, or not infringed. An authorized generic or non-infringing alternative formulation could enter under a different risk profile.

The relevant commercial date is therefore not a single patent-expiration date. It is the earliest date on which an approved competing product can launch without material injunction, settlement restriction, or regulatory delay.

Which companies are challenging or competing with Tirosint?

Competition falls into four groups:

1. Generic levothyroxine tablet manufacturers, including large multisource suppliers.
2. Branded tablet manufacturers, including AbbVie’s Synthroid franchise and other established brands.
3. Liquid levothyroxine suppliers and compounders.
4. Future softgel, oral-solution, and alternative-delivery developers.

Generic tablets exert the greatest price pressure but do not directly replicate Tirosint’s excipient profile or dosage form. Compounded liquid levothyroxine may address individualized dosing but generally lacks the same commercial consistency, regulatory positioning, and national distribution.

A direct competitor would need to match four attributes: reliable levothyroxine solubilization or dispersion, long-term stability, low-excipient composition, and scalable packaging. A product that matches only the active ingredient is unlikely to displace Tirosint in its core segments.

What manufacturing and intellectual-property barriers affect competitors?

Softgel manufacturing

Softgel production requires control of gelatin viscosity, shell thickness, fill weight, seam integrity, drying, oxygen exposure, and dose uniformity. Levothyroxine is highly potent at microgram doses, so small fill or concentration errors can create clinically meaningful dose variation.

The principal barriers include:

• Precision fill-weight control
• Uniform distribution of levothyroxine sodium
• Shell compatibility
• Moisture management
• Long-term potency retention
• Stability-indicating analytical methods
• High-throughput inspection and rejection systems

These barriers create manufacturing know-how even where patent protection is narrow.

Oral-solution manufacturing

Tirosint-SOL requires control of solubility, pH, concentration, container compatibility, microbial quality, and ampule fill accuracy. Levothyroxine’s low dose increases the importance of validated mixing and sampling methods.

Competitors may seek a formulation without ethanol. That approach could improve pediatric and institutional acceptability but may require a different solubilization strategy, surfactant system, pH range, or packaging material.

Packaging and delivery devices

The package is part of the product strategy. Unit-dose ampules support dosing accuracy but increase material usage and packaging expense. Multidose bottles could reduce cost but introduce preservative, microbial, and dose-measurement challenges.

Delivery-device patents and compatibility data can create practical barriers even when formulation patents expire. Oral syringes, feeding tubes, and elastomeric components can adsorb or retain low-dose levothyroxine, requiring comparative performance testing.

What generic launch risks exist for Tirosint?

A generic launch would face several potential paths:

Launch path	Risk to Tirosint	Likely commercial effect
Generic softgel with comparable excipients	High	Direct price and substitution pressure
Generic liquid with different excipients	Medium to high	Expands liquid competition
Generic tablet	Medium	Indirect pressure through formulary substitution
Compounded liquid	Low to medium	Localized competition
Authorized generic	High	Accelerates price erosion while preserving formulation access

The most material threat is a therapeutically equivalent softgel or oral solution that obtains FDA approval with a lower acquisition cost. A tablet generic would not fully reproduce the patient experience but could weaken payer coverage and prior-authorization support.

Paragraph IV litigation risk depends on the patents listed for the relevant NDA, the applicant’s certification, and the patent holder’s litigation response. A first-filed Paragraph IV applicant may obtain a 180-day period of generic exclusivity under the Hatch-Waxman framework if statutory requirements are met.[7]

How strong is the Tirosint patent estate?

The estate is strongest where claims cover the specific dosage form, excipient combination, concentration range, stability profile, or packaging configuration used in the marketed product.

Its practical strength is lower where:

• Claims depend on broad functional language.
• A competitor can use a different excipient system.
• The patent covers an optional rather than essential product attribute.
• The same clinical objective can be achieved with a tablet, suspension, or compounded formulation.
• Manufacturing trade secrets are not exposed in the patent claims.

For investors and licensing teams, the most valuable assets may be formulation protocols, analytical methods, manufacturing controls, supplier qualification, and clinical evidence supporting substitution resistance. These assets can remain commercially relevant after narrow formulation claims expire.

What licensing and partnership opportunities exist?

Potential transaction opportunities include:

• Licensing a preservative-free liquid formulation
• Acquiring a non-gelatin softgel platform
• Partnering for pediatric or hospital distribution
• Developing a multidose bottle or oral-syringe presentation
• Licensing a bioequivalence strategy for a generic softgel
• Supplying specialized ampules or barrier packaging
• Expanding into markets where levothyroxine liquid access is limited

A partner with a different excipient platform could target a white-space product: a stable, ethanol-free, gelatin-free, low-excipient oral solution. Such a product would address two limitations of the current portfolio while preserving the core Tirosint value proposition.

What revenue exposure does Tirosint create?

Tirosint revenue is exposed to four commercial variables:

1. The price premium over generic tablets.
2. The proportion of patients retained through insurance restrictions.
3. The rate of switching to lower-cost levothyroxine products.
4. The availability of direct softgel or liquid competitors.

Its revenue resilience is strongest in patients with documented intolerance, repeated treatment instability, dysphagia, or complex dosing needs. Its exposure is greatest in payer channels that treat all levothyroxine products as interchangeable and require step therapy through low-cost tablets.

A practical commercial strategy is to preserve premium positioning in specialized segments while expanding payer evidence around adherence, dose stability, reduced switching, and administration convenience. FDA labeling supports the product’s formulation description, but broader economic claims require clinical and health-economic evidence.[1][2]

Key Takeaways

• Tirosint capsules use gelatin, glycerin, and water, while Tirosint-SOL uses glycerol, water, and ethanol.
• The commercial differentiation is the minimal-excipient formulation and alternative dosage forms, not a new active ingredient.
• Tirosint-SOL has the strongest opportunity in pediatric, geriatric, dysphagia, enteral-feeding, and complex gastrointestinal populations.
• Softgel and oral-solution manufacturing create meaningful technical barriers because levothyroxine is administered at microgram doses.
• Direct generic risk is highest from an approved softgel or liquid product, not from conventional tablets alone.
• Patent value depends on claim coverage for the marketed formulation, dosage form, concentration, stability, and packaging.
• The strongest future white space is a stable, ethanol-free, gelatin-free, low-excipient liquid formulation.
• Commercial durability will depend on payer access, physician confidence, patient retention, and manufacturing quality after patent expiry.

FAQs

Is Tirosint lactose-free?

Yes. Tirosint’s listed capsule ingredients are gelatin, glycerin, and water. Lactose is not listed in the FDA prescribing information.[1]

Does Tirosint contain gluten?

The product is marketed as gluten-free, and gluten-containing excipients are not listed in the FDA formulation description.[1]

Is Tirosint-SOL better than Tirosint capsules?

They address different administration needs. Tirosint-SOL is more suitable for patients who cannot swallow capsules or need liquid dose flexibility. Tirosint capsules may be preferable for patients who want a solid dosage form without the ethanol-containing liquid formulation.

Can a competitor copy Tirosint’s excipients after patent expiry?

A competitor may be able to use similar excipients after relevant patent rights expire, but it must independently satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, stability, manufacturing quality, labeling, and packaging.

Is Tirosint a biologic or a biosimilar product?

No. Tirosint contains levothyroxine sodium, a synthetic small-molecule thyroid hormone. It is regulated through the NDA and abbreviated new drug application frameworks, not the biologic license application and biosimilar pathways.

References

1. U.S. Food and Drug Administration. (2024). Tirosint (levothyroxine sodium) capsules: Prescribing information. IBSA Pharma Inc.

2. U.S. Food and Drug Administration. (2024). Tirosint-SOL (levothyroxine sodium) oral solution: Prescribing information. IBSA Pharma Inc.

3. U.S. Food and Drug Administration. (2017). Levothyroxine sodium products: Guidance for industry. Center for Drug Evaluation and Research.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

5. Google Patents. (n.d.). Patent search database. https://patents.google.com/

6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

7. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research.